[Individually risk-adapted antiemetic step therapy].
作者信息
Bremer K
机构信息
Klinik für Hämatologie und Onkologie, Augusta-Kranken-Anstalt, Bochum.
出版信息
Dtsch Med Wochenschr. 1994 Apr 22;119(16):598-604. doi: 10.1055/s-2008-1058736.
PMID:8162844
Abstract
摘要
相似文献
1
[Individually risk-adapted antiemetic step therapy].
Dtsch Med Wochenschr. 1994 Apr 22;119(16):598-604. doi: 10.1055/s-2008-1058736.
2
Blueprint for the control of radiation-induced nausea and vomiting. Discussion.
Acta Oncol. 2004 Sep;43 Suppl 15:23-4. doi: 10.1080/11001700410016170.
3
5-HT3-receptor antagonists in the control of delayed-onset emesis.
Anticancer Res. 2003 May-Jun;23(3C):2773-82.
4
First choice for radiation-induced nausea and vomiting--the efficacy and safety of granisetron.
Acta Oncol. 2004 Sep;43 Suppl 15:19-22. doi: 10.1080/11001700410016161.
5
Is there a pharmacological basis for differences in 5-HT3-receptor antagonist efficacy in refractory patients?
Cancer Chemother Pharmacol. 2005 Sep;56(3):231-8. doi: 10.1007/s00280-005-1033-0. Epub 2005 Apr 19.
6
Site(s) and mechanisms of the anti-emetic action of 5-HT3 receptor antagonists: a discussion of Professor Naylor's paper.
Br J Cancer Suppl. 1992 Dec;19:S12-3.
7
In search of the ideal antiemetic.
Acta Oncol. 2004 Sep;43 Suppl 15:13-8. doi: 10.1080/11001700410016152.
8
Optimising antiemetic therapy: what are the problems and how can they be overcome?
Curr Med Res Opin. 2005 Jun;21(6):885-97. doi: 10.1185/030079905X46313.
9
Antiemetic drugs.
Medsurg Nurs. 2009 Sep-Oct;18(5):309-13; quiz 314.
10
[Type-3 serotonin receptor blockaders (5-HT3)--a new class of antiemetic preparations].
Eksp Klin Farmakol. 1994 Jul-Aug;57(4):72-5.
引用本文的文献
1
One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient.
Support Care Cancer. 2009 Jan;17(1):23-32. doi: 10.1007/s00520-008-0445-x. Epub 2008 Jun 5.
Zotero 插件